Lung cancer is well established as a highly heterogeneous tumor that harbors various gene alterations including mutations in EGFR, KRAS, BRAF, PD-L1, and PIK3CA, as well as ALK rearrangement and HER2 amplification. This evidence concerns the gene ERBB2 and neoplasm.